The US Food and Drug Administration has granted de novo authorization to UK-based Angle's Parsortix device, making it the first device approved by the regulator capable of capturing circulating tumor cells (CTC).
Specifically, the authorization covers the use of Parsortix in metastatic breast cancer patients and comes nearly two years after the...